Blueprint Medicines [BPMC] vs Vertex [VRTX] Detailed Stock Comparison
Blueprint Medicines
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Blueprint Medicines wins in 7 metrics, Vertex wins in 10 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Blueprint Medicines | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -120.99 | 32.82 | Blueprint Medicines |
| Price-to-Book Ratio | 24.43 | 7.05 | Vertex |
| Debt-to-Equity Ratio | 208.50 | 8.89 | Vertex |
| PEG Ratio | -137.72 | 25.16 | Blueprint Medicines |
| EV/EBITDA | -53.14 | 24.22 | Blueprint Medicines |
| Profit Margin (TTM) | -27.70% | 31.86% | Vertex |
| Operating Margin (TTM) | -27.50% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -47.71% | 22.77% | Vertex |
| Return on Assets (TTM) | -9.75% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-197.22M | $-978.00M | Blueprint Medicines |
| 1-Year Return | 12.60% | -21.75% | Blueprint Medicines |
| Price-to-Sales Ratio (TTM) | 14.89 | 10.62 | Vertex |
| Enterprise Value | $8.42B | $116.19B | Vertex |
| EV/Revenue Ratio | 14.97 | 10.18 | Vertex |
| Gross Profit Margin (TTM) | 98.12% | 86.90% | Blueprint Medicines |
| Revenue per Share (TTM) | $9 | $44 | Vertex |
| Earnings per Share (Diluted) | $-2.51 | $-3.83 | Blueprint Medicines |
| Beta (Stock Volatility) | 0.83 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Blueprint Medicines vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Blueprint Medicines | 0.00% | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% |
| Vertex | -2.42% | -20.68% | -21.40% | -14.68% | -22.01% | -9.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Blueprint Medicines | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
| Vertex | -21.75% | 24.45% | 37.13% | 167.78% | 912.82% | 2,065.03% |
Performance & Financial Health Analysis: Blueprint Medicines vs Vertex
| Metric | BPMC | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $8.37B | $121.28B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 5,799,940 | 1,390,330 |
| 90 Day Avg. Volume | 4,343,357 | 1,229,373 |
| Last Close | $129.46 | $366.54 |
| 52 Week Range | $73.04 - $129.65 | $364.66 - $519.88 |
| % from 52W High | -0.15% | -29.50% |
| All-Time High | $129.65 (Jul 16, 2025) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -0.15% | -29.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.56% | 0.12% |
| Quarterly Earnings Growth | -0.99% | 0.03% |
| Financial Health | ||
| Profit Margin (TTM) | -0.28% | 0.32% |
| Operating Margin (TTM) | -0.28% | 0.39% |
| Return on Equity (TTM) | -0.48% | 0.23% |
| Debt to Equity (MRQ) | 208.50 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.30 | $67.01 |
| Cash per Share (MRQ) | $8.92 | $24.90 |
| Operating Cash Flow (TTM) | $-145,552,000 | $-562,900,000 |
| Levered Free Cash Flow (TTM) | $-20,779,750 | $-438,500,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Blueprint Medicines vs Vertex
| Metric | BPMC | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -120.99 | 32.82 |
| Forward P/E | -137.72 | 25.16 |
| PEG Ratio | -137.72 | 25.16 |
| Price to Sales (TTM) | 14.89 | 10.62 |
| Price to Book (MRQ) | 24.43 | 7.05 |
| Market Capitalization | ||
| Market Capitalization | $8.37B | $121.28B |
| Enterprise Value | $8.42B | $116.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 14.97 | 10.18 |
| Enterprise to EBITDA | -53.14 | 24.22 |
| Risk & Other Metrics | ||
| Beta | 0.83 | N/A |
| Book Value per Share (MRQ) | $5.30 | $67.01 |
Financial Statements Comparison: Blueprint Medicines vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BPMC | VRTX |
|---|---|---|
| Revenue/Sales | $149.41M | $2.96B |
| Cost of Goods Sold | $2.80M | $407.50M |
| Gross Profit | $146.61M | $2.56B |
| Research & Development | $91.89M | $978.40M |
| Operating Income (EBIT) | $-41.09M | $1.15B |
| EBITDA | $23.55M | $1.34B |
| Pre-Tax Income | $1.29M | $1.28B |
| Income Tax | $789,000 | $250.10M |
| Net Income (Profit) | $496,000 | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BPMC | VRTX |
|---|---|---|
| Cash & Equivalents | $122.25M | $4.67B |
| Total Current Assets | $702.07M | $10.01B |
| Total Current Liabilities | $250.58M | $3.78B |
| Long-Term Debt | $409.17M | $1.65B |
| Total Shareholders Equity | $342.13M | $16.50B |
| Retained Earnings | $-2.41B | $10.25B |
| Property, Plant & Equipment | $97.66M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BPMC | VRTX |
|---|---|---|
| Operating Cash Flow | $13.41M | $404.90M |
| Capital Expenditures | $-1.83M | $-40.70M |
| Free Cash Flow | $-56.31M | $778.20M |
| Debt Repayment | $-4.11M | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | BPMC | VRTX |
|---|---|---|
| Shares Short | 3.13M | 4.19M |
| Short Ratio | 0.62 | 3.34 |
| Short % of Float | 0.05% | 0.02% |
| Average Daily Volume (10 Day) | 5,799,940 | 1,390,330 |
| Average Daily Volume (90 Day) | 4,343,357 | 1,229,373 |
| Shares Outstanding | 63.71M | 256.94M |
| Float Shares | 60.00M | 255.58M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 1.09% | 0.98% |
Dividend Analysis & Yield Comparison: Blueprint Medicines vs Vertex
| Metric | BPMC | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |